vs
EXACT SCIENCES CORP（EXAS）与Virtu Financial, Inc.（VIRT）财务数据对比。点击上方公司名可切换其他公司
Virtu Financial, Inc.的季度营收约是EXACT SCIENCES CORP的1.1倍（$969.9M vs $878.4M），Virtu Financial, Inc.净利率更高（14.4% vs -9.8%，领先24.2%），EXACT SCIENCES CORP同比增速更快（23.1% vs 16.3%），Virtu Financial, Inc.自由现金流更多（$495.6M vs $120.4M），过去两年Virtu Financial, Inc.的营收复合增速更高（22.8% vs 17.4%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Virtu Financial, Inc.是一家总部位于美国的高频交易企业，专注于金融市场的自动化交易业务，拥有行业领先的交易技术研发与落地能力，于2015年在纳斯达克证券交易所正式挂牌上市。
EXAS vs VIRT — 直观对比
营收规模更大
VIRT
是对方的1.1倍
$878.4M
营收增速更快
EXAS
高出6.9%
16.3%
净利率更高
VIRT
高出24.2%
-9.8%
自由现金流更多
VIRT
多$375.1M
$120.4M
两年增速更快
VIRT
近两年复合增速
17.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $969.9M |
| 净利润 | $-86.0M | $139.9M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | 35.4% |
| 净利率 | -9.8% | 14.4% |
| 营收同比 | 23.1% | 16.3% |
| 净利润同比 | 90.1% | 48.7% |
| 每股收益（稀释后） | $-0.45 | $1.54 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASVIRT
| Q4 25 | $878.4M | $969.9M | ||
| Q3 25 | $850.7M | $824.8M | ||
| Q2 25 | $811.1M | $999.6M | ||
| Q1 25 | $706.8M | $837.9M | ||
| Q4 24 | $713.4M | $834.3M | ||
| Q3 24 | $708.7M | $706.8M | ||
| Q2 24 | $699.3M | $693.0M | ||
| Q1 24 | $637.5M | $642.8M |
净利润EXASVIRT
| Q4 25 | $-86.0M | $139.9M | ||
| Q3 25 | $-19.6M | $77.6M | ||
| Q2 25 | $-1.2M | $151.2M | ||
| Q1 25 | $-101.2M | $99.7M | ||
| Q4 24 | $-864.6M | $94.1M | ||
| Q3 24 | $-38.2M | $60.0M | ||
| Q2 24 | $-15.8M | $66.6M | ||
| Q1 24 | $-110.2M | $55.8M |
毛利率EXASVIRT
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — | ||
| Q1 24 | 70.0% | — |
营业利润率EXASVIRT
| Q4 25 | -9.4% | 35.4% | ||
| Q3 25 | -3.0% | 21.8% | ||
| Q2 25 | -0.3% | 34.7% | ||
| Q1 25 | -13.6% | 26.7% | ||
| Q4 24 | -122.8% | 24.3% | ||
| Q3 24 | -5.6% | 20.8% | ||
| Q2 24 | -3.8% | 22.4% | ||
| Q1 24 | -16.7% | 21.8% |
净利率EXASVIRT
| Q4 25 | -9.8% | 14.4% | ||
| Q3 25 | -2.3% | 9.4% | ||
| Q2 25 | -0.1% | 15.1% | ||
| Q1 25 | -14.3% | 11.9% | ||
| Q4 24 | -121.2% | 11.3% | ||
| Q3 24 | -5.4% | 8.5% | ||
| Q2 24 | -2.3% | 9.6% | ||
| Q1 24 | -17.3% | 8.7% |
每股收益（稀释后）EXASVIRT
| Q4 25 | $-0.45 | $1.54 | ||
| Q3 25 | $-0.10 | $0.86 | ||
| Q2 25 | $-0.01 | $1.65 | ||
| Q1 25 | $-0.54 | $1.08 | ||
| Q4 24 | $-4.69 | $1.03 | ||
| Q3 24 | $-0.21 | $0.64 | ||
| Q2 24 | $-0.09 | $0.71 | ||
| Q1 24 | $-0.60 | $0.59 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $1.1B |
| 总债务越低越好 | — | $2.0B |
| 股东权益账面价值 | $2.4B | $1.6B |
| 总资产 | $5.9B | $20.2B |
| 负债/权益比越低杠杆越低 | — | 1.29× |
8季度趋势，按日历期对齐
现金及短期投资EXASVIRT
| Q4 25 | $964.7M | $1.1B | ||
| Q3 25 | $1.0B | $707.9M | ||
| Q2 25 | $858.4M | $752.1M | ||
| Q1 25 | $786.2M | $723.6M | ||
| Q4 24 | $1.0B | $872.5M | ||
| Q3 24 | $1.0B | $701.4M | ||
| Q2 24 | $946.8M | $684.8M | ||
| Q1 24 | $652.1M | $399.6M |
总债务EXASVIRT
| Q4 25 | — | $2.0B | ||
| Q3 25 | — | $2.0B | ||
| Q2 25 | — | $1.7B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $1.7B | ||
| Q1 24 | — | $1.7B |
股东权益EXASVIRT
| Q4 25 | $2.4B | $1.6B | ||
| Q3 25 | $2.5B | $1.5B | ||
| Q2 25 | $2.5B | $1.4B | ||
| Q1 25 | $2.4B | $1.3B | ||
| Q4 24 | $2.4B | $1.3B | ||
| Q3 24 | $3.2B | $1.2B | ||
| Q2 24 | $3.2B | $1.2B | ||
| Q1 24 | $3.1B | $1.2B |
总资产EXASVIRT
| Q4 25 | $5.9B | $20.2B | ||
| Q3 25 | $5.9B | $21.3B | ||
| Q2 25 | $5.8B | $19.3B | ||
| Q1 25 | $5.7B | $17.5B | ||
| Q4 24 | $5.9B | $15.4B | ||
| Q3 24 | $6.7B | $14.4B | ||
| Q2 24 | $6.7B | $13.9B | ||
| Q1 24 | $6.4B | $12.8B |
负债/权益比EXASVIRT
| Q4 25 | — | 1.29× | ||
| Q3 25 | — | 1.40× | ||
| Q2 25 | — | 1.24× | ||
| Q1 25 | — | 1.33× | ||
| Q4 24 | — | 1.39× | ||
| Q3 24 | — | 1.41× | ||
| Q2 24 | — | 1.41× | ||
| Q1 24 | — | 1.42× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $518.4M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $495.6M |
| 自由现金流率自由现金流/营收 | 13.7% | 51.1% |
| 资本支出强度资本支出/营收 | 3.6% | 2.4% |
| 现金转化率经营现金流/净利润 | — | 3.71× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $485.6M |
8季度趋势，按日历期对齐
经营现金流EXASVIRT
| Q4 25 | $151.7M | $518.4M | ||
| Q3 25 | $219.9M | $-68.7M | ||
| Q2 25 | $89.0M | $62.8M | ||
| Q1 25 | $30.8M | $15.0M | ||
| Q4 24 | $47.1M | $599.0M | ||
| Q3 24 | $138.7M | $112.1M | ||
| Q2 24 | $107.1M | $490.8M | ||
| Q1 24 | $-82.3M | $-395.4M |
自由现金流EXASVIRT
| Q4 25 | $120.4M | $495.6M | ||
| Q3 25 | $190.0M | $-76.7M | ||
| Q2 25 | $46.7M | $57.6M | ||
| Q1 25 | $-365.0K | $9.2M | ||
| Q4 24 | $10.7M | $586.6M | ||
| Q3 24 | $112.6M | $106.2M | ||
| Q2 24 | $71.2M | $486.9M | ||
| Q1 24 | $-120.0M | $-398.2M |
自由现金流率EXASVIRT
| Q4 25 | 13.7% | 51.1% | ||
| Q3 25 | 22.3% | -9.3% | ||
| Q2 25 | 5.8% | 5.8% | ||
| Q1 25 | -0.1% | 1.1% | ||
| Q4 24 | 1.5% | 70.3% | ||
| Q3 24 | 15.9% | 15.0% | ||
| Q2 24 | 10.2% | 70.3% | ||
| Q1 24 | -18.8% | -61.9% |
资本支出强度EXASVIRT
| Q4 25 | 3.6% | 2.4% | ||
| Q3 25 | 3.5% | 1.0% | ||
| Q2 25 | 5.2% | 0.5% | ||
| Q1 25 | 4.4% | 0.7% | ||
| Q4 24 | 5.1% | 1.5% | ||
| Q3 24 | 3.7% | 0.8% | ||
| Q2 24 | 5.1% | 0.6% | ||
| Q1 24 | 5.9% | 0.4% |
现金转化率EXASVIRT
| Q4 25 | — | 3.71× | ||
| Q3 25 | — | -0.89× | ||
| Q2 25 | — | 0.42× | ||
| Q1 25 | — | 0.15× | ||
| Q4 24 | — | 6.37× | ||
| Q3 24 | — | 1.87× | ||
| Q2 24 | — | 7.37× | ||
| Q1 24 | — | -7.08× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
VIRT
暂无分部数据
